CABOMETYX 60 mg film-coated tablets clinical trials
7 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
This study is testing a medicine called CABOMETYX for advanced thyroid cancer that hasn't responded to radioactive iodine treatment. Researchers are looking at blood samples to understand how the medicine works and if certain signs in the blood can predict who will benefit most.
For: Advance Radioactive-Iodine Refractory Differentiated Thyroid CancerSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.
This study looks at a new medicine called cabozantinib for young people with a type of bone cancer called osteosarcoma. It compares cabozantinib plus supportive care with supportive care alone to see if it helps stop the cancer from growing.
For: Osteosarcoma in Children · Osteosarcoma in Adolescents and Young Adults · OsteosarcomaPoland · France · Netherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
This study is testing a medicine called Cabometyx for people with advanced kidney cancer. It's for those whose cancer has grown even after previous treatment. Doctors want to see how well Cabometyx shrinks the cancer.
For: Unresectable · Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint InhibitorsGermany · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3
This study is testing a new medicine, cabozantinib, for people with a type of advanced neuroendocrine cancer. Doctors want to see how well it controls the cancer and if it improves quality of life. It's a phase II trial, meaning it's still in early stages of testing.
For: Neuroendocrine Neoplasia Neuroendocrine TumorAustria · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo)
This study looks at a new treatment called cabozantinib for liver cancer (hepatocellular carcinoma) in people who haven't responded to previous treatments. It aims to see how well it stops the cancer from growing and if it's safe to use. Patients will take tablets.
For: Hepatocellular carcinomaItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
This study is testing different medicines for people with advanced kidney cancer (non-clear cell renal carcinoma) that has spread. It's looking for personalised treatments to see which ones shrink the cancer and how long they keep it under control. The goal is to find better ways to treat this type of cancer.
For: Metastatic non-clear cell renal cell carcinomaDenmark - AuthorisedTherapeutic exploratory (Phase II)
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation
This study is looking at a new drug called Cabozantinib for a type of lung cancer called non-small cell lung cancer (NSCLC). It's for people whose cancer has specific genetic changes related to a protein called MET. Researchers want to see how well the drug shrinks tumours.
For: Non small-cell lung cancerItaly